Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

Phase 2 trial results showed an improvement in MASH with no worsening of fibrosis in all treatment groups compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

Shares of Praxis Precision Medicines (NASDAQ: PRAX) leaped on Monday after the clinical-stage biopharmaceutical company ...

Treatment with TSND-201 was associated with statistically significant improvement in PTSD symptoms. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSND-201 ...

A single jab of a breakthrough gene therapy could reverse hearing loss in people within weeks, according to new research. The cutting-edge therapy improved hearing in children and adults with ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

Novartis’ ITVISMA, approved a month ago by the US FDA, used at Sheikh Khalifa Medical City under the supervision of the ...

When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...

Abu Dhabi marks landmark achievement in becoming the first in the world to deliver ITVISMA (onasemnogene abeparvovec) for the ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...